Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 8
From BugSigDB
Reviewed Marked as Reviewed by KateRasheed on 2025-4-24
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Patients with Polyps (P group)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Patients with Colorectal Cancer stage II (C2)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients diagonosed with Colorectal Cancer stage II (C2)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 92
- Group 1 sample size Number of subjects in the case (exposed) group
- 101
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 1 Month
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- ANOVA
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Alpha Diversity
- Richness Number of species
- decreased
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-4-24
Source: Figure 4 and 2C
Description: Boxplot analysis of key differential genera from diagnosis model and dominant phyla
Abundance in Group 1: increased abundance in Patients with Colorectal Cancer stage II (C2)
| NCBI | Quality Control | Links |
|---|---|---|
| Gemella | ||
| Parvimonas | ||
| Peptostreptococcus | ||
| Fusobacteriota |
Revision editor(s): Nithya, KateRasheed
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-4-24
Source: Figure 4 and 2C
Description: Boxplot analysis of key differential genera from diagnosis model and dominant phyla
Abundance in Group 1: decreased abundance in Patients with Colorectal Cancer stage II (C2)
| NCBI | Quality Control | Links |
|---|---|---|
| Corynebacterium | ||
| Ezakiella | ||
| Fenollaria | ||
| Finegoldia | ||
| Peptoniphilus | ||
| Staphylococcus | ||
| Varibaculum | ||
| Pseudomonadota |
Revision editor(s): Nithya
